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Abstract
Background: Anthracyclines (AC), widely used and effective anticancer agents, are known to induce both acute
and chronic declines in cardiovascular health, ranging in severity from asymptomatic, subclinical dysfunction to
substantial cardiomyopathy leading to congestive heart failure and death. There is substantial evidence that
physical activity, higher levels of cardiorespiratory fitness, and exercise therapy can help prevent cardiovascular
disease. Moreover, animal studies have shown that exercise performed concomitantly with AC treatment may
attenuate early cardiac damage that results from AC exposure. Our primary objective is to assess the feasibility
of a 12-week aerobic exercise training (AET) program in patients receiving AC-based chemotherapy.
Methods/design: This is a prospective, single-arm (pre-post-test design), feasibility study of a supervised 12-week
progressive, light-to-moderate to moderate-to-vigorous intensity AET program for patients (18–65 years) receiving
AC chemotherapeutic treatment for a primary/non-recurrent breast cancer or hematological malignancy. Both
feasibility (e.g., participant recruitment, program adherence, safety) and intervention outcome (e.g., biological
markers of cardiotoxicity, aerobic capacity, quality of life) measures will be collected. The AET program will include
two, 45-min community-based exercise sessions (treadmill or cycle) per week for a total of 12 weeks. All exercise
sessions will be supervised by trained exercise specialists.
Discussion: Data from the EXACT study will be evaluated to determine the need to refine patient recruitment
methods and general acceptability of the AET program. Preliminary data on the effects of the AET intervention on
pertinent cardiac and health outcomes will also be evaluated and used to inform future studies in terms of the
most appropriate outcome measure(s) to adopt and sample size estimation.
Trial registration: ClinicalTrails.gov, NCT02471053
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Background
As the numbers of cancer survivors grow, the long-term
adverse effects of cancer therapy are becoming increas-
ingly apparent. Perhaps the most prominent of these are
the toxic effects on the heart (cardiotoxicity) which may
lead to cardiac dysfunction and increased risk of cardio-
vascular disease (CVD) [1]. Of note, data indicate that
the magnitude of CVD risk for long-term survivors may
exceed the risk of recurrent cancer and represents the
leading non-cancer cause of death among survivors of
breast cancer and Hodgkin’s disease [2–5]. Thus, it is
clear that the long-term cardiotoxic effects of cancer
therapy represent a significant concern for many cancer
survivors.
While the advent of modern cancer therapies has
translated into substantially improved survival, several
widely used therapies have been shown to increase the
risk of cardiac toxicity. Cancer therapeutics have been
associated with a number of long-term cardiac complica-
tions such as decreased left ventricular function, hyper-
tension, arrhythmias, cardiac ischemia, pericardial and
valvular disease, cardiomyopathy, and congestive heart
failure [6, 7]. For example, anthracyclines (AC), a che-
motherapeutic agent commonly utilized in the manage-
ment of many adult cancers including breast and
hematological malignancies, are known to be cardio-
toxic. The risk of cardiotoxicity associated with AC im-
pacts its benefit/risk profile and ultimately limits the
drugs clinical utility [6–10]. The adverse effects of AC
can be associated with acute, early-onset, and chronic
cardiomyocyte injury that can range in severity from
asymptomatic subclinical left ventricular dysfunction to
significant cardiac impairment and symptomatic heart
failure [9]. Although several factors underlie the cardio-
toxic effects of AC on the heart, the primary causative
factor underlying acute cardiotoxicity appears to involve
an inflammatory response while the formation of free
radicals appears to be related to chronic AC cardiotoxi-
city [8] both of which can contribute to the development
and progression of CVD [11–13].
The risk of developing cardiotoxicity appears to be
predominately related to the total cumulative AC dose.
Although the incidence of AC-induced cardiotoxicity ap-
pears to be greatest at doxorubicin dosages exceeding
700 mg/m2 [6, 7], cardiotoxicity has been reported in pa-
tients who have received doses as low as 100 mg/m2,
suggesting that there is no reliably “safe” dose [14]. Spe-
cifically, the risk of heart failure has been reported in 3
to 5 % of patients that receive a cumulative dose of
400 mg/m2. As cumulative dose increases, so too does
the incidence of heart failure. For example, at cumulative
doses of 550 and 700 mg/m2, the incidence of heart
failure has been reported as 7–26 and 18–48 %, respect-
ively [15]. Furthermore, it has been reported that the
cumulative incidence of heart failure in elderly breast
cancer patients 10 years post-AC-based treatment was
38 % [15].
Patients with a pre-existing history of hypertension or
CVD, those who receive AC concurrently with other
known cardiotoxic agents (e.g., trastuzumab), advanced
age, female gender, or those treated with mediastinal ra-
diation are at a greater risk of developing AC-mediated
CVD [8, 14]. Lifestyle factors (e.g., physical inactivity,
smoking, high BMI) may also contribute to the increased
risk of CVD in this population [16].
While AC cardiotoxicity is thought to cause irrevers-
ible cardiomyocyte damage (i.e., type I), recent data sug-
gests that early detection and intervention may mitigate
or reverse myocardial cell injury. Cardinale and col-
leagues [17] prospectively evaluated the left ventricular
ejection fraction (LVEF) in 2625 AC-treated breast and
non-Hodgkin lymphoma patients before, during, and
after chemotherapy for a median follow-up of 5.2 years.
They found that cardiotoxicity (defined as a >10 %
reduction in LVEF from baseline and an end LVEF of
<50 %) occurred in 9 % of patients. The majority of these
cases (98 %) emerged within the first year of completing
AC therapy (median time to development of cardiotoxicity
was 3.5 months). Upon identification of cardiotoxicity,
early heart failure therapy was initiated and full (11 %) or
partial (71 %) recovery was reported in 82 % of the cases.
Although this study provides data to support early detec-
tion and treatment of cardiotoxicity, challenges remain.
Groarke and Nohria [18] note that the early identification
of cardiotoxicity often involves the reconsideration of
chemotherapy protocols resulting in either dose reduc-
tions or treatment substitutions. Given that 97 % of the re-
ported deaths in the Cardinale et al. [17] study were
cancer related, the balance of minimizing the risk of cardi-
otoxicity against antineoplastic efficacy becomes a signifi-
cant and ongoing concern. Accordingly, intervention
strategies that complement existing antineoplastic treat-
ment strategies while decreasing the risk of cardiotoxicity
are needed.
Physical activity and exercise has long been established as
a powerful tool in the prevention and treatment of chronic
diseases, including some cancers and CVD [19, 20]. Ex-
ercise has also been shown to reduce all-cause mortality
as well as both cancer [21] and cardiovascular-related
mortality [22]. Importantly, while exercise can increase
aerobic fitness as well as modify traditional CVD risk
factors [23], exercise may also help protect the heart
from the associated cardiotoxic effects of AC-based
therapy [24]. For example, several animal studies have
shown that regular exercise performed prior to or con-
comitantly with AC treatment helps to preserve cardiac
function [25–30]. Pre-treatment exercise has also been
shown to decrease AC accumulation in the heart, which
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helps to decrease cardiotoxicity [31]. Furthermore, stud-
ies of AC-mediated cardiotoxicity have shown that regu-
lar exercise can increase antioxidant defenses [29, 32]
and decrease inflammatory markers [33, 34]. These
changes decrease the impact of AC-mediated oxidative
stress and inflammation, thus improving myocardiocyte
survival [25, 35, 36]. Thus, while much is left to be ex-
plored, exercise may prove effective in the management
of AC-mediated cardiotoxicity as well as improving
overall cancer survival.
Despite the increased risk of cardiotoxicity and the
potential benefits of exercise therapy, the efficacy of
exercise as a therapeutic intervention for the prevention
of AC-mediated cardiotoxicity remains speculative. Ac-
cordingly, the purpose of this study is to examine the
feasibility and potential efficacy of a 12-week, individual-
ized aerobic exercise training (AET) program to mitigate
cardiac toxicity and patient outcomes associated with
AC-based chemotherapy.
The specific objectives of the study are as follows: (1)
to examine feasibility outcomes (e.g., recruitment, pro-
gram adherence, and safety) and (2) to explore the
effects of the exercise program on biological markers of
AC-mediated cardiotoxicity (e.g., levels of inflammation)
as well as patient-centered outcomes (e.g., increased aer-
obic capacity, quality of life). We hypothesize that an in-
dividualized AET program for cancer patients receiving
active AC-based treatment will be both safe and feasible
with an anticipated adherence of 66–85 % [37]. We
further hypothesize that the AET program will result in
improvements in the overall levels of physical activity,
aerobic fitness, and quality of life. Given the dearth of
knowledge surrounding both the measurement of cardiac
biomarkers and the cardioprotective nature of aerobic
exercise in human models, no a priori hypotheses have
been made. Instead, this study will serve to inform future
iterations.
Methods/design
Study design and procedures
The protocol was drafted in accordance with the SPIRIT
2013 statement [38]. This is a single-arm, prospective
(pre-post) feasibility study of a supervised 12-week light-
to-moderate to moderate-to-vigorous intensity AET
program. The study flow is presented for each separate
cancer site in Fig. 1. Potential participants will be identi-
fied and screened for preliminary eligibility by their
medical oncologist/hematologist during a regular office
visit at the Queen Elizabeth II Health Sciences Center
(QEII HSC) in Halifax, Nova Scotia, Canada. Pending
preliminary screening for study eligibility and medical
approval to participate, potential participants will be
approached by a member of the medical staff to seek
permission to refer them to the research coordinator to
discuss the details of the study. Pending approval to be
contacted by the research team, eligible participants will
be provided with a detailed review of the study and in-
formed consent will be sought by the research coordin-
ator. Eligible participants who provide informed consent
will undergo additional cardiovascular risk and fitness
assessment (i.e., cardiopulmonary exercise test (CPET))
to determine study suitability and ability to safely par-
ticipate in a low-to-moderate or moderate-to-vigorous
aerobic training program. Those meeting the study
criteria will then complete a pre-exercise baseline as-
sessment (week 0) of anthropometric measures, select
cardiac biomarkers, lifestyle behaviors, and quality of
life. Based on the findings of the exercise stress test and
baseline assessments, an individualized, bi-weekly AET
program will be developed (weeks 1–12). Pending the
completion of the 12-week training program, partici-
pants will repeat the exercise stress and cardiac func-
tion tests and the assessments measured at baseline
(week 13). The study is registered with ClinicalTrails.gov
(NCT02471053).
Setting and participants
The EXercise to prevent AnthrCycline-based Cardio-
Toxicity (EXACT) feasibility study will seek to recruit
20 participants receiving active AC-based chemotherapy
for either a primary breast or hematological cancer at
the QEII HSC. All study assessments and exercise ses-
sions will take place at an affiliated center located in
close proximity to the cancer clinics. Potential partici-
pants will be identified based on the following inclusion
criteria: (1) participants are between the ages of 18 and
65 at the time of study initiation; (2) are within 8 weeks
receiving the first dose of an AC-based chemothera-
peutic treatment for a primary, non-metastatic, HER2-
negative breast cancer, or hematological malignancy; (3)
are scheduled to receive a minimum dose of 100 mg/m2
of doxorubicin (or equivalent) [39]; (4) have undergone
a pre-treatment cardiac function test; (5) are willing to
participate in a twice-weekly, 12-week community-based
AET program; and (6) have medical consent from their
medical oncologist/hematologist to participate in an
exercise study. Any patients that meet the inclusion
criteria, but have (1) significant cognitive limitations; (2)
significant cardiovascular disease (i.e., myocardial infarc-
tion, cerebrovascular disease, peripheral vascular disease,
congestive heart failure, or cardiomyopathy) or any
known contraindication to exercise; (3) previous history
of cancer; or (4) known bone metastases will be excluded
from the study.
Intervention
In addition to standard oncologic care, all participants will
be enrolled in a 12-week AET program to commence
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following baseline testing. Participants will be asked to
complete two supervised exercise sessions on non-
consecutive days each week. Session intensity will range
from light-to-moderate (as defined as 35 to 55 % heart
rate reserve (HRR)) or moderate-to-vigorous activity
(defined as 55 to 85 % HRR). Participants will use a wrist-
worn heart rate monitor (Polar Electro Canada Inc., QC)
to ensure that they are training within the appropriate tar-
get heart rate zone. Exercise sessions will begin with a
group warm-up activity (5 min), followed by 20–45 min of
individually tailored aerobic activity (based on the max-
imum heart rate achieved in the absence of any clinical
symptoms during the baseline CPET) and ending with a
cool down (10 min). Aerobic activities will include walking
on a treadmill and/or cycling on an upright or recumbent
cycle ergometer. A nonlinear approach will be used to
optimize adaptations to the exercise stimulus, and session
intensity will be inversely related to session duration
(Fig. 2) [37]. We have elected to adopt a nonlinear exercise
prescription based on the foundational principles of exer-
cise physiology, individualization, specificity, progressive
overload, and recovery [37, 40, 41]. Baseline physiological
testing of the target system will be measured using an in-
cremental CPET [42]. The results of the CPET, peak
workload, and peak exercise heart rate will allow for an in-
dividualized exercise prescription, rather than a generic
exercise prescription based on age-predicated maximum
heart rate which can result in under- or overprescription
of exercise for the participant [37]. With regards to speci-
ficity, aerobic exercise was chosen to elicit cardiovascular
physiological adaptations, as the purpose of the study
centers around cardiotoxicity. Progressive overload will be
used to guide the pattern of exercise intensity and
duration over the 12-week program [40, 41]. The varied
intensity between training sessions will be used to con-
tinually perturb the cardiovascular system in order to
create a physiological response. However, caution will be
exercised to ensure that overtraining does not occur as
Fig. 1 Participant flow through the EXACT study representing each cancer site separately
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this could result in excessive fatigue and/or injury [37].
Thus, the exercise protocol has been designed with
periods of progressive overload (either higher intensity or
longer duration) with built-in periods of rest (days off)
and active recovery (lower intensity, shorter duration).
This type of exercise intervention has been previously
utilized in oncology settings and has shown that there are
favorable adherence rates (66 to 85 % adherence) and a
low incidence of adverse events [37].
To achieve a total of 150 min of light-to-moderate or
moderate-to-vigorous activity each week, participants
will be asked to engage in additional home-based aerobic
activities (e.g., walking). Participants will be asked to
keep an activity diary including a record of their resting
heart rate, type of exercise performed, duration of the
exercise, and maximum heart rate during all supervised
and home-based exercise sessions.
Strategies to enhance participant recruitment, adherence,
and retention
Efforts to optimize participant engagement will include
on-site, face-to-face recruitment and physician endorse-
ment. Several strategies to improve participant adherence
and retention will be also be employed including group-
based, individually tailored exercise training sessions; per-
sonalized performance feedback (e.g., weekly activity diary
review); follow-up phone calls to inquire about missed
sessions; ability to make-up missed session(s) over the
course of the 12-week intervention; and scheduling
flexibility.
Primary outcomes
Participant accrual, adherence, retention, and safety
The primary feasibility outcome measures for this study
will include variables associated with participant recruit-
ment, adherence, retention, and safety. Recruitment rate
will be calculated by the number of patients who con-
sent to participate divided by the number of deemed eli-
gible to participate by their primary care oncologist/
hematologist. Program adherence will be calculated by
counting the actual number of sessions that the partici-
pant engaged in divided by the recommended number of
weekly sessions. Participants will also be asked to record
their activity duration (time) and intensity (as measured
by heart rate) following each training session in order to
calculate exercise volume. Participant retention will be
Fig. 2 Twelve-week aerobic exercise training program [37]. Note: heart rate reserve (HRR) = % of target intensity (HRmax − HRrest) + HRrest
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determined by reporting the number of participants who
complete baseline and post-intervention testing. Pro-
gram safety will be assessed by weekly tracking and
monitoring the number of adverse events or injuries that
occur during the duration of the study. An investigators
meeting will be held every 3 months to review and dis-
cuss all reported minor adverse events (e.g., muscle stiff-
ness, activity-related fatigue) and injuries (e.g., muscle
strain) for early risk identification and modification of
study procedures as needed. All serious adverse events
will be immediately disseminated to all study investiga-
tors for review and reported to the Nova Scotia Health
Authority Research Ethics Board. There are currently no
stopping guidelines for this trial.
Secondary outcomes
Baseline demographics (age, sex, ethnicity, education,
employment status, family income), lifestyle behaviors
(general health, aerobic fitness, physical activity behaviors,
sleep habits, tobacco use, and alcohol consumption), and
medical history (cancer diagnosis, cancer treatment(s) re-
ceived, comorbid health conditions, markers of cardiac
risk [43]) will be collected by a combination of self-report
and participant-consented medical record review.
Cardiac function
Resting baseline and post intervention LVEF will be per-
formed on all participants with a multigated acquisition
(MUGA) scan. MUGA is a non-invasive, cost-effective,
and reliable measure of heart function by tracking blood
flow through the ventricles. Serial monitoring will per-
mit for the early detection of decreased left ventricular
function [44].
Cardiorespiratory fitness
CPETs will be performed to determine peak aerobic
capacity (VO2 peak) that the participant reaches in the
absence of any clinical symptoms (e.g., fatigue, leg pain,
changes in ECG). The CPETs will be performed in ac-
cordance with the American Heart Association (AHA)
guidelines [42]. In brief, all participants will complete
either the BRUCE treadmill protocol or a RAMP treadmill
protocol [42]. A standard 12-lead ECG will be recorded
concurrently with the CPET [42]. Resting ECG and post-
exercise ECG will also be recorded. Blood pressure will be
recorded manually at rest prior to the test, during the
CPET (at the end of every exercise stage), and during
recovery [40]. All tests will be performed by a CPET tech-
nician and supervised by a cardiologist. Upon completion,
all CPET results will be reviewed by a cardiologist to de-
termine if there is any evidence of undiagnosed pre-
existing cardiovascular disease or any contraindications to
participating in the study exercise protocol.
In general, maximal symptom-limited exercise testing
(CPET) is a reasonably safe procedure [45]. The American
Thoracic Society/American College of Chest Physicians
report that the number of life-threatening complications
or deaths was approximately 2 to 5 per 100,000 tests [45].
Statistics, based on a review of the literature, published by
the AHA report the number of sudden cardiac deaths
which ranges from 0 to 5 per 100,000 tests [46]. Similarly,
systematic reviews suggest that CPET is safe for cancer
patients. For example, a review of oncology studies that
utilized exercise testing reports that adverse events were
reported in less than 15 % of the studies and that there
were no reports of death [47]. Another systematic review
reported that adverse events occurred in only 1 % of
oncology patients that performed exercise testing [48].
Together, the evidence clearly indicates that CPETs can be
safely administered to individuals receiving and/or recov-
ering from cancer treatment.
Cardiac biomarkers
Blood samples will be collected from the participants
prior to and immediately following the 12-week exercise
intervention to determine the participant’s lipid profile
and fasting glucose. Markers of cardiac injury including
high-sensitivity troponin (hs-TNT), N-terminal pro-
brain natriuretic peptide (NTproBNP), and C-reactive
protein (CRP) levels as well as various systemic markers
of inflammation will also be collected. These tests will
occur within 7 days of starting and ending the program.
Samples will be processed at the QEII HSC to quantify
levels of lipids, fasting glucose, hs-TNT, NTproBNP, and
CRP. Serum also will be extracted from the blood samples
in order to quantify markers of systemic inflammation (cy-
tokines). A BioPlex Pro human cytokine immunoassay will
be used to quantify the levels of 27 different cytokines
(e.g., IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-17, TNFα). Assays
will be performed as per manufacturer’s instructions. A
MAGPIX Suspension Array System will be used to
analyze the cytokine assay. All serum samples will be
stored at −80 °C until they are required for analysis. With
participant consent, blood samples will be stored for use
for future related studies.
Total physical activity
To capture additional activity behaviors, total physical
activity across four life domains (i.e., job-related, house
and yard work, recreation, and active transportation) will
be assessed using the long version of the International
Physical Activity Questionnaire (IPAQ) pre- and post-
intervention. Physical activity levels as well as continu-
ous values of MET-minutes per week (MET =metabolic
equivalent of task) will be calculated according to the
IPAQ scoring protocol [49, 50].
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Self-reported time spent sitting (sedentary behaviors)
will also be assessed by the IPAQ by calculating the sum
of the time spent sitting (e.g., at a desk, watching televi-
sion, reading, and time spent sitting in a vehicle for the
purpose of transportation). Time spent sitting will be
calculated according to the IPAQ scoring protocol [50].
The IPAQ tool has demonstrated acceptable reliability
and validity in adults 18–65 years of age and is com-
parable to other self-reported measures of physical ac-
tivity [49].
Anthropometrics
Body weight will be assessed to the nearest 0.1 kg, and
height will be measured to the nearest 0.1 cm using a
Tanita body composition analyzer. Body mass index will
be calculated as the weight in kilograms divided by the
height in meters squared (kg/m2). Waist girth measure-
ments will be taken clear of participant clothing at the
top of the iliac crest to the nearest 0.1 cm [41].
Patient-reported outcomes
Cancer-related fatigue and disease-specific quality of life
will be assessed pre- and post-intervention using cancer-
specific, self-administered Functional Assessment of
Cancer Therapy (FACT) tools [51–55]. The FACT tools
are reliable and valid measures of disease-specific quality
of life and fatigue [51–55].
Sample size
For this feasibility study, we will aim to recruit 20 breast
and hematological cancer patients over a course of
12 months. Preliminary data will inform power analyses
for a larger randomized trial. Likewise, the number of
patients that we are able to recruit during this period
will determine the number of collaborating centers
needed to obtain sufficient participant recruitment for
future studies.
Project management
The conduct and management of the feasibility study
will be the responsibility of the research group com-
prised of the study investigators and research support
staff. The research coordinator will be responsible for
the day-to-day management of the trial including partici-
pant recruitment and retention, assisting with outcome
assessments, design and conduct of the exercise interven-
tion, and data management. The research coordinator and
principal investigators (MK and SG) will meet weekly to
discuss participant recruitment, outcome assessments,
intervention delivery, participant safety, and data manage-
ment. Additional meetings with medical co-investigators
will be held every 3 months or more frequently as needed.
Ethical governance and dissemination
This study has received ethical approval from the Nova
Scotia Health Authority Research Ethics Board (REB file:
NSHA ROMEO File #: 1019999). Any protocol amend-
ments will be submitted for further review and approval.
Study findings will be presented at conferences and
submitted for publication in peer-reviewed journals.
Only those team members who fulfill authorship criteria
will be included as authors on any future publications.
Professional writers will not be employed.
Confidentiality and access to data
All study personnel will be trained in the requirement of
participants’ confidentiality according to the Tri-Council
Policy Statement: Ethical Conduct for Research Involv-
ing Humans. Participant identification numbers will be
assigned upon study enrollment, and access to person-
ally identifiable information will be limited to members
of the research team. All data files will be stored on a
password-protected computer in a secure research
laboratory.
Data management and analysis
De-identified data will be double entered in SPSS version
22, and basic descriptive statistics will be conducted to
describe the study sample and outcomes. Rates for
process measures (e.g., recruitment, adherence) will be
reported. Exploratory correlational analyses will also be
conducted to examine the relationship between program
adherence and secondary outcome measures. Reasons
for non-participation and attrition will be recorded to
inform future recruitment and retention strategies. Pro-
gram safety will be determined by examining the total
number adverse events that occur over the duration of
the 12-week exercise program. The total number of ad-
verse events over the course of the study will be divided
by the total number of participant hours to determine
the number of adverse events per participant hour. Sec-
ondary outcome measures will be assessed at baseline
(week 0) and post-intervention (week 13) using descrip-
tive statistics and 95 % confidence interval estimation.
Change between time points will also be assessed in this
way, and within-group correlations will be calculated
between the two time points. The data will be used to
determine the most appropriate outcome measure for
the main study and in sample size calculations required
for a future grant submission. Descriptive statistics and
confidence intervals will also be used to examine the
trends in the biomarker data. This information will be
used to determine which markers to focus on in future
grant submissions. Should we find that the biomarker
data is normally distributed, then a 95 % confidence
interval for paired normally distributed data will be used;
otherwise, a non-parametric approach will be taken.
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Discussion
Given the established antineoplastic effectiveness of AC-
based therapies, non-competing strategies to prevent or
decrease the risk of AC-mediated cardiotoxicity and car-
diovascular complications are needed to improve sur-
vivorship outcomes. Despite initial promising findings,
the role of exercise in the management of AC-mediated
cardiotoxicity remains to be fully elucidated. The pri-
mary objective of the EXACT study is to shed light on
the feasibility of a supervised, progressive aerobic exercise
program for patients undergoing active cancer treatment.
We will also attempt to elucidate how exercise may pro-
vide incremental benefit with respect to the prevention of
AC-mediated cardiotoxicity.
On the whole, this study represents an important first
step towards designing large-scale studies to understand
how regular aerobic exercise impacts heart health in pa-
tients undergoing active AC treatment. This feasibility
study will provide additional insight into the practical
barriers to exercise in patients undergoing active chemo-
therapy and will allow for the development of strategies
to improve the acceptance and adherence to appropriate
regimes. Given the relatively small, geographically dis-
persed population in Nova Scotia, it is likely that there
will be a need for multi-center trials that include a home
and/or community-based component to maximize par-
ticipant adherence. Findings from this study will inform
the safety, design, and systematic conduct of such future
trials. Furthermore, the exploration of non-invasive and
safe screening outcome measures (i.e., cardiac biomarkers,
LVEF, exercise stress testing) that underlie the potential
cardioprotective nature of aerobic exercise will serve to
better elucidate the mechanisms of benefit and inform
future studies [56]. This will subsequently improve the
proper measure and interpretation of the effectiveness of
exercise training in maximizing cardiovascular health and
to minimize cardiotoxicity of the AC-based chemothera-
peutic regimes. Ultimately, it is our goal to be able to iden-
tify patients and survivors at the greatest risk of adverse
cardiovascular events, evaluate the effects of exercise to
ameliorate this risk, and foster change in the current stan-
dards of care to reflect improved patient quality of life and
clinical outcomes.
Trial status
ClinicalTrials.gov identifier NCT02471053 (protocol
version 1.0; 27 May 2015). Recruitment for the study
commenced in February 2016.
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